[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370228-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370228-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","gynecologic-oncology-in-2024-breakthrough-trials-and-evolving-treatment-strategies-for-cervical-uterine-corpus-and-ovarian-cancers","Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers","","This 2025 review article compiles major results from clinical trials published in 2024 that were considered to meaningfully influence practice in gynecologic oncology. It covers cervical cancer trials spanning early, locally advanced, and recurrent/metastatic settings, including SHAPE, INTERLACE, KEYNOTE-A18, BEATcc, and COMPASSION-16. It summarizes updated endometrial and leiomyosarcoma survival data, then reviews ovarian cancer survival findings across PRIMA, DUO-O, ATHENA-combo, FIRST-ENGOT-OV44, and briefly addresses DESTINY-PanTumor02.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/gynecologic-oncology-in-2024-breakthrough-trials-and-evolving-treatment-strategies-for-cervical-uterine-corpus-and-ovarian-cancers/370228/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/gynecologic-oncology-in-2024-breakthrough-trials-and-evolving-treatment-strategies-for-cervical-uterine-corpus-and-ovarian-cancers/370228.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",17,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which cervical cancer trials were highlighted in this 2024 review?","Question",{"text":63,"@type":64},"The review highlights SHAPE for early cervical cancer, INTERLACE and KEYNOTE-A18 for locally advanced disease, and BEATcc and COMPASSION-16 for recurrent/metastatic cervical cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What uterine corpus cancer data were summarized?",{"text":68,"@type":64},"For endometrial cancer, updated survival data from NRG-GY018, RUBY, AtTEnd, and DUO-E are described, and first survival data from the LMS-04 trial are included for leiomyosarcoma.",{"name":70,"@type":61,"acceptedAnswer":71},"Which ovarian cancer studies and additional trial were addressed?",{"text":72,"@type":64},"The article follows final overall survival results of PRIMA and then covers DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 in different disease contexts, with brief discussion of DESTINY-PanTumor02 as a trastuzumab deruxtecan basket trial.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370228,1790387602,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","J Gynecol Oncol. 2025 Jan;36(1):e72 [https://doi.org/10.3802/jgo.2025.36.e72](https://doi.org/10.3802/jgo.2025.36.e72)[ ](https://doi.org/10.3802/jgo.2025.36.e72)pISSN 2005-0380·eISSN 2005-0399  \nReview Article  \nReceived: Jan 10, 2025  \nRevised: Jan 12, 2025  \nAccepted: Jan 13, 2025  \nPublished online: Jan 20, 2025  \nCorrespondence to  \nDong Hoon Suh  \nDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea.  \nEmail: [sdhwcj@naver.com](sdhwcj@naver.com)  \n*Sung Jong Lee and Ji Geun Yoo equally contributed to this report.  \n© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nSung Jong Lee  [https://orcid.org/0000-0002-6077-2649](https://orcid.org/0000-0002-6077-2649)[ ](https://orcid.org/0000-0002-6077-2649)Ji Geun Yoo  [https://orcid.org/0000-0001-5359-8729](https://orcid.org/0000-0001-5359-8729)[ ](https://orcid.org/0000-0001-5359-8729)Jin Hwi Kim  [https://orcid.org/0000-0002-1591-1611](https://orcid.org/0000-0002-1591-1611)[ ](https://orcid.org/0000-0002-1591-1611)[Jeong-Yeol Park](Jeong-Yeol Park)  [https://orcid.org/0000-0003-2475-7123](https://orcid.org/0000-0003-2475-7123)[ ](https://orcid.org/0000-0003-2475-7123)[Jung-Yun Lee](Jung-Yun Lee)  [https://orcid.org/0000-0001-7948-1350](https://orcid.org/0000-0001-7948-1350)[ ](https://orcid.org/0000-0001-7948-1350)[Yoo-Young Lee](Yoo-Young Lee)  [https://orcid.org/0000-0001-5902-9877](https://orcid.org/0000-0001-5902-9877)[ ](https://orcid.org/0000-0001-5902-9877)Dong Hoon Suh  [https://orcid.org/0000-0002-4312-966X](https://orcid.org/0000-0002-4312-966X)  \nGynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers  \nSung Jong Lee ,1,* Ji Geun Yoo ,2,* Jin Hwi Kim ,3 Jeong-Yeol Park ,4 Jung-Yun Lee ,5 Yoo-Young Lee ,6 Dong Hoon Suh  7  \n1Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea  \n2Department of Obstetrics and Gynecology, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon, Korea  \n3Department of Obstetrics and Gynecology, Uijeongbu St Mary’s Hospital, The Catholic University of Korea, Uijeongbu, Korea  \n4Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea  \n5Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea 6Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea  \n7Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea  \nABSTRACT  \nThis review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly ad","cbCaitIQFopaXwpD","https://ap.wps.com/l/cbCaitIQFopaXwpD","pdf",1225167,15,"English","# Abstract\n# Introduction\n# Cervical Cancer\n## Early cervical cancer\n# Uterine Corpus Cancer\n# Ovarian Cancer\n# Conclusion","[{\"question\":\"Which cervical cancer trials were highlighted in this 2024 review?\",\"answer\":\"The review highlights SHAPE for early cervical cancer, INTERLACE and KEYNOTE-A18 for locally advanced disease, and BEATcc and COMPASSION-16 for recurrent/metastatic cervical cancer.\"},{\"question\":\"What uterine corpus cancer data were summarized?\",\"answer\":\"For endometrial cancer, updated survival data from NRG-GY018, RUBY, AtTEnd, and DUO-E are described, and first survival data from the LMS-04 trial are included for leiomyosarcoma.\"},{\"question\":\"Which ovarian cancer studies and additional trial were addressed?\",\"answer\":\"The article follows final overall survival results of PRIMA and then covers DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 in different disease contexts, with brief discussion of DESTINY-PanTumor02 as a trastuzumab deruxtecan basket trial.\"}]","Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers | PDF",1790187479,38,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60695882f96b14edd6cc0383a07716d8.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e0e0de9acaba75f624fdce4b03ea8de.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/263c7a8a58821e31b573670f7583aa21.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef28c22bacfdbf4d8701c864d06199bd.webp",980,1306]